|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS |
|
|
|
|
|
|
A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial
|
Oliver Sartor joins Charles Ryan to talk about the VISION trial, a trial testing the PSMA-617 agent, The novel therapeutic drug 177Lu-PSMA-617 is a prostate-specific membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
|
|
|
|
|
|
|
|
|
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman
|
Charles Ryan and Michael Hofman share in a discussion on the use of new imaging techniques in prostate cancer, the sensitivity of imaging and the use of theranostics PSMA targeted therapies for metastatic castrate-resistant prostate cancer.
|
|
|
|
|
|
|
|
|
The Future of Advanced Prostate Cancer Imaging
|
Stefano Fanti, MD
|
Stefano Fanti presents his point of view on the future of prostate cancer imaging. He shares his thoughts on the use of conventional imaging such as CT and bone scan and why they should be regarded as obsolete, and why novel imaging such as PET PSMA and MRI should be incorporated into practice immediately.
|
|
|
|
|
|
|
|
|
|
|
RECENT DATA FROM CONFERENCES WORLDWIDE |
|
|
|
SNMMI Therapeutics Conference 2019 |
Operationalizing Your Practice for 177Lu-PSMA Based Therapies
|
Phillip Kuo, MD, PhD
|
Phillip Kuo, MD, PhD, gave an overview discussing important radiation safety considerations and logistical considerations for starting 177-Lutetium-PSMA targeted therapies.
|
|
|
|
|
Overview of the Treatment Landscape in Castration-Resistant Prostate Cancer
|
Tanya Dorff, MD
|
Dr. Tanya Dorff gave an overview highlighting the major changes and evolving areas in advanced prostate cancer management. Her talk focused on non-metastatic castrate-resistant prostate cancer (m0CRPC), oligometastatic prostate cancer, and metastatic CRPC (mCRPC).
|
|
|
|
|
Current and Future Role of Radium 223 in Prostate Cancer
|
Phillip Koo, MD, FACS
|
Dr. Phillip Koo gave a talk on the role that Radium-223 currently has in the management of metastatic prostate cancer. There is data showing that the mortality increases as the disease progresses from metastases in the lymph node to bone to visceral tissue.
|
|
|
|
|
Operationalizing Your Practice for 223Ra-Dichloride |
Phillip Koo, MD, FACS |
In this presentation Dr. Phillip Koo gave an overview of the clinical operations for a successful Radium 223 program. For the implementation of such a clinic, there are three factors that need to be considered – the clinical, operations, and business leaders. |
|
|
|
|
Regulatory and Radiation Safety Requirements for Radiopharmaceutical Therapy
|
Michael Sheetz, MS, CHP, DABMP
|
Dr. Michael Sheetz presented on the regulatory and radiation safety requirements for radiopharmaceutical therapy. He began with some basic facts on the radiation regulatory oversight.
|
|
|
|
|
|
|
|
|
Co-Managing the Patient with Metastatic Castration-Resistant Prostate Cancer
|
Phillip Koo, MD, FACS
|
Dr. Phillip Koo spoke on the concept of co-managing the patient with mCRPC. For treatment to be standardized we need to establish consistent care, lower costs, and improved outcomes. They are known oncological clinical pathways that standardize the care processes using evidence-based medicine. In the US there are 60 health insurance plans that are implementing oncology pathways. There are over 170 million individuals in the US who are covered by these insurance plans, which are potentially being treated under a plan-sponsored pathway.
|
|
|
|
|
Current Status of 177 Lu-PSMA Targeted Therapies and Where Will we be in the Near Future
|
Phillip Kuo, MD, PhD
|
In this presentation, Phillip Kuo, MD, PhD, described the current status of late-stage clinical trials, and the future landscape of 177-Lutetium-PSMA targeted therapies. The prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in prostate cancer and tends to increase with disease aggressiveness. There has been a significant increase in research related to PSMA in the last several years.
|
|
|
|
|
Overview of the Meeting and Roadmap to the Future of Radionuclide Therapy
|
Daniel Alexander Pryma, MD
|
Concluding this meeting, Dr. Daniel Pryma gave an overview of the important topics that were covered in the meeting.
|
|
|
|
|
|
|